

## References

- [1] Hoeijmakers, J. H. J., *Nature*, 2001, **411**, 366.
- [2] Jackson, S. P., *Carcinogenesis*, 2002, **23**, 687.
- [3] Boulton, S. et al., *Carcinogenesis*, 1997, **17**, 2285.
- [4] Hardcastle, I. R. et al., *J. Med. Chem.*, 2005, **48**, 7829.
- [5] Zhao, Y. et al., *Cancer Res.*, 2006, **66**, 5354.

128

POSTER

#### Unraveling therapeutic bio-signatures through pathway mapping at the single cell level using an analysis platform for simplified interrogation of complex data sets

A. Cappione<sup>1</sup>, L. Zieske<sup>1</sup>, R. Lefebvre<sup>1</sup>, D. King<sup>1</sup>. <sup>1</sup>Guava Technologies Inc, Research & Development, Hayward, USA

Solid tumors comprise genetically heterogeneous cell populations whose growth and survival depends on the complex interplay of distinct, yet overlapping, signaling networks. A major challenge in developing a course of therapy is determining which signaling nodes to target for a specific malignancy. Profiles from siRNA gene silencing are integral to mapping disease-specific signaling cascade(s) and provide insight to key targets for therapeutic intervention. Successful siRNA screening relies not solely upon optimizing transfection, but also cell analysis systems capable of high content screening (HCS) at the single cell level, within overall populations (sample well), and across multiple data sets. The Guava EasyCyte™ Plus flow cytometer, with integrated Guava® Simplicity software, provides a revolutionary new platform for cell-based analysis. The software's intuitive architecture and ease of use facilitates the comparison of multiple experimental conditions or disease states through heat-map visualization. To demonstrate, a mini-drug screening was performed. Following exposure to a panel of 80 cytoactive compounds, cells were assayed for multiple parameters of apoptotic induction as well as monitoring alterations in mitotic state. Parallel to screening, siRNA silencing was performed to identify genes that impact Camptothecin (CPT)-induced apoptosis. Knockdown efficiency of each gene target was examined via intracellular staining and optimized for each cell line prior to functional screening. "Hit" compounds were further tested in combination with siRNA knockdown. For this study, changes in the phosphorylation state of multiple proteins were also measured. Briefly, apoptotic assays following gene silencing identified enhancers (PTEN) and inhibitors (GSK3a) of CAM-induced cell death as well as modulators of cell cycle progression (MDM2, CHK1). Moreover, it was evident that certain genes are functionally linked and thus part of the same or overlapping networks. "Hit" screening identified cytochalasin as a potential therapeutic with similar biological profiles as CPT. However, phospho-mapping suggests their specific mechanisms of action are quite different. In summary, this experimental methodology, when used in concert with Guava Technologies' cell analysis platform and Simplicity software, significantly expedites the drug discovery process by providing a means for extraction of key biological findings from complex experimental results.

129

POSTER

#### Design, synthesis and evaluation of bivalent conformationally constrained Smac mimetics as a new class of anticancer agents

H. Sun<sup>1</sup>, J. Lu<sup>1</sup>, L. Bai<sup>1</sup>, Z. Nikolovska-Coleska<sup>1</sup>, C. Yang<sup>1</sup>, S. Qiu<sup>1</sup>, X. Ling<sup>2</sup>, M. Guo<sup>2</sup>, D. Yang<sup>3</sup>, S. Wang<sup>1</sup>. <sup>1</sup>University of Michigan, Internal Medicine, Ann Arbor, MI, USA; <sup>2</sup>Ascenta Therapeutics Inc. (Shanghai), R&D Center, Shanghai, China; <sup>3</sup>Ascenta Therapeutics Inc., R&D Center, Philadelphia, PA, USA

Second mitochondria-derived activator of caspase (Smac) is a protein released from mitochondria in response to apoptotic stimuli. Smac promotes apoptosis, at least in part, by effectively antagonizing several members of inhibitor of apoptotic proteins (IAPs), including XIAP, cIAP-1 and cIAP-2, by targeting one or more BIR domains in IAPs. We designed and synthesized a series of non-peptidic, cell-permeable, bivalent small-molecules which mimic the dimeric Smac protein for targeting IAPs (bivalent Smac mimetics). We performed extensive evaluations of these bivalent Smac mimetics for their interaction with IAP proteins and their activity and mechanism in cancer cells. Our studies show that these Smac mimetics bind to XIAP, cIAP-1 and cIAP-2 with low nano-molar affinities. They function as extremely potent XIAP antagonists by concurrently targeting both the BIR2 and BIR3 domains. Consistent with their potent binding affinities to cIAP-1, these bivalent Smac mimetics potently and effectively induce rapid degradation of cIAP-1 protein in cancer cells. Our data showed that the lengths of the linker in these bivalent Smac mimetics have a significant effect on their ability in induction of cIAP-1 degradation. These bivalent Smac mimetics potently inhibit cell growth with IC<sub>50</sub> values between low nanomolar and sub-micromolar and effectively

induce apoptosis in a subset of cancer cell lines. Their potencies in inhibition of cell growth and induction of apoptosis nicely correlate with their ability in induction of cIAP-1 degradation. The most potent bivalent Smac mimetic SM-164 is capable of inducing of robust apoptosis in cancer cells at concentrations as low as 1 nM and effectively inhibits tumor growth in the MDA-MB-231 xenograft model. Importantly, SM-164 shows a minimal toxicity to normal cells *in vitro* and to mouse tissues *in vivo*. Taken together, our data provide strong evidence that bivalent Smac mimetics may have a great therapeutic potential for the treatment of human cancer by induction of apoptosis through targeting multiple IAP proteins.

130

POSTER

#### Structure-activity relationships for a library of C2-aryl substituted monomeric pyrrolo[2,1-c][1,4]benzodiazepines (PBD) antitumour agents

M. Coffils<sup>1</sup>, D.I. Jodrell<sup>2</sup>, S.M. Guichard<sup>2</sup>, J.A. Hartley<sup>1</sup>, P.W. Howard<sup>1</sup>, D. Antonow<sup>1</sup>, D.E. Thurston<sup>1</sup>. <sup>1</sup>Spirogen Ltd, 29/39 Brunswick Square, London, United Kingdom; <sup>2</sup>University of Edinburgh, CRUK Pharmacology and Drug Development Centre, Edinburgh, United Kingdom

There is growing interest in pyrrolo[2,1-c][1,4]benzodiazepine (PBD) antitumour agents as one example of this class, the synthetic DNA-interactive sequence-selective PBD dimer SJG-136, is likely to move into Phase II clinical trials later this year. Unlike this synthetic agent which contains two PBD units and works by cross-linking DNA, the naturally-occurring PBDs isolated from various *Streptomyces* species are monomeric compounds that form single covalent bonds to the N2 of guanine in the DNA minor groove in a similar manner to the recently licensed marine-derived anticancer agent trabectedin. We have previously reported that insertion of an aryl group at the C2-position of the C-ring of monomeric PBDs can dramatically enhance their overall *in vitro* cytotoxicity and their selectivity towards particular cell lines (especially melanoma). Novel C2-aryl PBDs of this type have not been observed in nature, and the precise role of the C2-aryl substituent in enhancing their activity was not understood. We report here the use of combinatorial technologies to synthesize a library of over 110 C2-aryl substituted monomeric PBD analogues via palladium-catalyzed cross-coupling. Each library member retains the C2/C3-endo unsaturation observed in the naturally occurring compounds, and the C2-aryl substituents contain a diverse array of ring types (including mono-, bi- and tricyclic systems) and heteroatoms (O, N and S). In addition, for comparative purposes, some library members contain C2-aliphatic alkenyl substituents (as found in the most potent natural product sibiromycin) or a combination of aryl and alkenyl substituents (i.e., C2-styryl derivatives). Biological evaluation of library members has confirmed that introduction of a C2-aryl group significantly enhances overall *in vitro* cytotoxicity and DNA-binding affinity with a good correlation between the two. The most active library members include the C2-aryl analogue SG2897 which has remarkable DNA-binding affinity (i.e.,  $T_m = 20.8^\circ\text{C}$ ) and cytotoxicity (e.g., IC<sub>50</sub> = 0.62 nM in SK-MEL-5 melanoma; 1.45 nM in K562 leukaemia) and is significantly more potent than the best natural product sibiromycin (i.e.,  $T_m = 16.3^\circ\text{C}$ , IC<sub>50</sub> = 10 nM in SK-MEL-5; 1.40 nM in K562) which lacked efficacy in clinical trials and, unlike SG2897, is problematic to synthesize. These data will be reported in full along with the results of preclinical studies on SG2897 presently underway.

131

POSTER

#### Specific induction of the p53 pathways by low dose cytotoxic drugs assessed by gene expression pattern analysis

M.L. Choong<sup>1</sup>, P.Z.K. Kwek<sup>1</sup>, H. Yang<sup>2</sup>, M.A. Lee<sup>1</sup>, D.P. Lane<sup>1</sup>. <sup>1</sup>Experimental Therapeutics Centre ASTAR, Assay Development Group, Singapore, Singapore; <sup>2</sup>Bioinformatics Institute ASTAR, Bioinformatics, Singapore, Singapore

**Background:** Induction of the p53 pathway is seen as a potentially exciting new therapeutic approach in human tumor therapy. Recently small molecule activators of the pathway have been identified by both biochemical and cell-based screens. Nutlin, a MDM2 inhibitor, has shown pre-clinical efficacy. Using expression arrays as a powerful method to determine small molecule specificity, we noted potent p53 activation by several known cytotoxic drugs at very low doses. Actinomycin D (ActD, a known DNA-interacting transcription inhibitor) and Leptomycin B (LMB, an inhibitor of exportin 1 driving nuclear protein export) both showed p53 activation in our reporter assay. LMB is too toxic to be used clinically while ActD is one of the older chemotherapy drugs which have been used in treatment of a variety of cancers. Potentially beneficial therapeutic use could be achieved if these compounds were shown to activate p53 pathways without the corresponding toxic effect. Literature reviews have demonstrated that at